Core Viewpoint - Stride, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price due to poor customer experiences related to platform changes [1][5]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. - The company previously reported "record demand" for its products and services, indicating a strong customer base [3]. Recent Developments - On October 28, 2025, Stride disclosed that its growth rate did not meet expectations due to poorly executed upgrades to its learning and technology platforms [5]. - The upgrades led to a "poor customer experience," resulting in higher withdrawal rates and lower conversion rates, which drove students away from the platform [5]. Financial Impact - Stride estimated a loss of approximately 10,000-15,000 enrollments due to the negative impact of the platform changes [5]. - Following the announcement, Stride's stock price plummeted by $83.48 per share, a decline of over 54%, from $153.53 on October 28, 2025, to $70.05 on October 29, 2025 [6].

Core Viewpoint - MoonLake Immunotherapeutics is facing a securities class action lawsuit due to alleged misrepresentations regarding its clinical data and the efficacy of its investigational drug sonelokimab, leading to significant stock price declines after disappointing trial results [2][4][5][7][8]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [5]. Group 2: Allegations and Legal Action - The lawsuit claims that MoonLake and its executives violated federal securities laws by providing misleading information about the clinical benefits of sonelokimab [2][4][6]. - The complaint is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in MoonLake common stock [4]. Group 3: Clinical Trial Results and Impact - MoonLake reported disappointing results from the VELA Phase 3 trials on September 28, 2025, with VELA-2 failing to meet its primary endpoint, raising doubts about the drug's regulatory approval and commercial viability [8]. - Following the announcement, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [8].

Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The class action lawsuit has been filed against CarMax and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [3]. Group 2: Financial Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [6]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million in the previous year [6]. Group 3: Stock Price Impact - Following the announcement of poor financial results on September 25, 2025, CarMax's stock price fell by $11.45 per share, or roughly 20%, from $57.05 to $45.60 [7]. - An additional drop of over 15% occurred after the unexpected departure of CEO Bill Nash and a weak preliminary Q3 2025 outlook on November 6, 2025 [7]. Group 4: Market Context - The lawsuit alleges that CarMax misrepresented the demand for its cars, which was temporarily boosted by U.S. tariffs, leading to a "pull forward" in demand prior to the tariffs taking effect [4][6]. - The unexpected departure of CEO Bill Nash is also under investigation to determine if CarMax properly assessed its portfolio of car loans [5].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud due to significant stock drops linked to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 26, 2025, to request to lead the case in the U.S. District Court for the Southern District of New York [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [4]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and posing health risks to customers [5]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to revelations about product quality issues, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [6]. - After the FDA published details of unauthorized modifications on March 25, 2025, the stock fell another $3.19 per share (over 4%) [7]. - A report by Hunterbrook on September 18 revealed severe issues, leading to a nearly 12% drop of $8.99 per share over two trading days [8].

Core Viewpoint - The MoonLake class action lawsuit alleges that the company and its executives made false statements regarding the efficacy of its drug candidate, sonelokimab, leading to significant financial losses for investors [1][3][5]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's sole drug candidate, sonelokimab (SLK), is primarily aimed at treating hidradenitis suppurativa (HS) [3]. Allegations of the Lawsuit - The lawsuit claims that MoonLake and its executives failed to disclose critical information about SLK, including its molecular targets and clinical efficacy compared to Union Chimique Belge's BIMZELX [4]. - It is alleged that SLK and BIMZELX share the same molecular targets, and SLK's unique Nanobody structure does not provide a superior clinical benefit [4]. - The lawsuit highlights that SLK's supposed increased tissue penetration did not translate to improved clinical efficacy [4]. Impact of the Allegations - Following the announcement of disappointing Phase 3 trial results on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - Investors who purchased MoonLake common stock during the class period can seek to become lead plaintiffs in the lawsuit, which allows them to represent the interests of all affected investors [6]. - The deadline for filing lead plaintiff motions is December 15, 2025 [2]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases [7].

Core Viewpoint - The Avantor class action lawsuit alleges that the company and its executives misrepresented the competitive positioning and financial health of Avantor, leading to significant stock price declines following disappointing financial results [3][4][5][6]. Group 1: Lawsuit Details - The lawsuit is titled "Building Trades Pension Fund of Western Pennsylvania v. Avantor, Inc." and seeks to represent purchasers of Avantor common stock, alleging violations of the Securities Exchange Act of 1934 [1]. - The lawsuit claims that Avantor's competitive positioning was weaker than publicly represented, and the company faced negative impacts from increased competition [3]. - The lead plaintiff motions must be filed by December 29, 2025, for those who suffered substantial losses [2]. Group 2: Financial Performance and Stock Impact - On April 25, 2025, Avantor reported weak first-quarter results, leading to a more than 16% drop in share price after the CFO acknowledged the impact of increased competition [4]. - On August 1, 2025, the company reported disappointing second-quarter results and reduced its full-year guidance, resulting in a more than 15% decline in share price [5]. - On October 29, 2025, Avantor announced weak third-quarter results, including a 5% decrease in organic revenue growth, causing a more than 23% drop in share price [6]. Group 3: Company Background - Avantor provides mission-critical products and services across various sectors, including biopharma, healthcare, and advanced technologies [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its significant recoveries in securities fraud cases, having recovered over $2.5 billion for investors in 2024 alone [8].

Core Viewpoint - The Six Flags Entertainment Corporation is facing a class action lawsuit alleging violations of the Securities Act of 1933 related to its merger with Cedar Fair, L.P., with claims that the company misrepresented its financial health and operational needs prior to the merger [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled "City of Livonia Employees' Retirement System v. Six Flags Entertainment Corporation" and was filed in the Northern District of Ohio [1]. - Purchasers of Six Flags common stock related to the merger have until January 5, 2026, to seek lead plaintiff status in the lawsuit [1]. - The lawsuit claims that the registration statement for the merger failed to disclose significant underinvestment in Legacy Six Flags, which required millions in additional capital to maintain operations [3]. Group 2: Financial Impact - On the merger closing date, July 1, 2024, Six Flags stock was trading above $55 per share, but it subsequently fell to as low as $20 per share, representing a nearly 64% decline [4]. - The lawsuit alleges that the company's executives misled investors about the financial condition of Legacy Six Flags, which undermined the rationale for the merger [3]. Group 3: Company Background - Six Flags is identified as an amusement park operator, and the lawsuit highlights the operational challenges faced by the company following a significant reduction in employee headcount aimed at cost-cutting [2][3]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, has a strong track record in prosecuting investor class actions and has recovered over $2.5 billion for investors in 2024 alone [5].

Core Viewpoint - An amended securities class action lawsuit has been filed against CarMax, Inc., expanding the class period to include purchases made between June 20, 2025, and November 5, 2025, with a lead plaintiff deadline set for January 2, 2026 [1]. Group 1: Allegations Against CarMax - The complaint alleges that CarMax's defendants made false and misleading statements regarding the company's growth prospects, claiming that the earlier growth in the 2026 fiscal year was merely a temporary benefit due to customer speculation about tariffs [2]. - It is asserted that the positive statements made by the defendants about CarMax's business and operations were materially misleading and lacked a reasonable basis throughout the class period [2]. Group 2: Lead Plaintiff Process - Investors in CarMax have until January 2, 2026, to seek appointment as a lead plaintiff representative of the class, or they may choose to remain absent class members [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of fraud and corporate misconduct [4].

Company Overview - Soleno Therapeutics, Inc. (NASDAQ: SLNO) is under investigation for potential violations of U.S. federal securities laws, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2]. Recent Developments - On March 26, 2025, Soleno announced FDA approval for VYKAT XR (diazoxide choline) extended-release tablets, intended for treating hyperphagia in individuals with Prader-Willi syndrome aged 4 and older [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for VYKAT XR due to adverse effects by the end of Q3 2025. The CEO acknowledged a disruption in the product's launch trajectory following a short seller report released in mid-August, which led to a decrease in start forms and an increase in discontinuations for non-serious adverse events [4]. Market Reaction - Following the earnings call and the revelation of the discontinuation rate, Soleno's share price experienced a decline of over 26% [4].

Nov 7, 2025 5:01 PM Eastern Standard Time Deadline Soon: Lantheus Holdings, Inc. (LNTH) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit Share LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 10, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Lantheus Holdings, Inc. ("Lantheus†or the "Company†) (NASDAQ: ...